Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-31

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and efficacy of brodalumab compared with placebo in participants with axial spondyloarthritis. Subjects will be randomized in a 1:1 ratio to brodalumab or placebo for the first part of the study. Subjects will then receive open label brodalumab for the remainder of the study. The entire study will be 312 weeks in duration for each subject.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)

NCT02985983

Axial Spondyloarthritis

COMPLETED PHASE3

Efficacy and Safety Study of SUNPG1622

NCT02980705

Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis

TERMINATED PHASE2

Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis

NCT00771030

Rheumatoid Arthritis

COMPLETED PHASE1/PHASE2

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

NCT01870284

Spondylitis, Ankylosing

WITHDRAWN PHASE3

Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate

NCT00950989

Rheumatoid Arthritis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Axial Spondyloarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Brodalumab

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Placebo will be administered subcutaneously

Placebo

Group Type PLACEBO_COMPARATOR

Brodalumab 210 mg

Intervention Type DRUG

210 mg brodalumab will be administered subcutaneously

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brodalumab 210 mg

210 mg brodalumab will be administered subcutaneously

Intervention Type DRUG

Placebo

Placebo will be administered subcutaneously

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject fulfills the ASAS classification criteria of axial spondyloarthritis (except Crohn's disease criterion) for \> 3 months with age of onset \< 45 years of age
* Subject has Bath Ankylosing Spondylitis DIsease Activity Index (BASDAI) score greater than or equal to 4 at screening and baseline
* Subject has spinal pain score (BASDAI question #2) greater than or equal to 4 at screening and baseline
* Subject has had adequate therapeutic trial (at least 4 weeks) of greater than or equal to 2 non-steroidal anti-inflammatory drgs (NSAIDs) at the maximum recommended dose unless contraindicated or subject is intolerant
* For subjects receiving non-biologic DMARDS subject has received treatment for greater than or equal to 3 months with a stable doe for greater than or equal to 4 weeks prior to initiation of IM
* For subjects receiving oral corticosteroids: the subject must be on a stable dose (not to exceed the equivalent of 10 mg of prednisone per day) for equal to or greater than 4 weeks prior to initiation of IMP

Exclusion Criteria

* Complete ankylosis (fusion) of the spine; Subject has a positive test for tuberculosis
* Subject has a planned surgical intervention between baeline and week 16
* Subject has an active infection or history of infections as follows (any active infection for which systemic anti-infectives were used within 28 day prior to the first MP dose
* A serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to the first IMP dose
* Recurrent or chronic infections or other active infection that, in the opinion ofthe investigator might cause this study to be detrimental to the subject)
* Subject has active Crohn's disease or a history of Crohn's disease
* Subject has active ulcerative colitis requiring daily use of immunosuppressive therapy
* Subject has had active fibromyalgia within the past 12 months
* Subject has a prior history of greater than 1 anti-TNF therapy for ankylosing spondylitis
* Subject has used commercially available or investigational biologic therapies for ankylosing spondylitis as follows

* Anti-tumor necrosis factor (TNF) therapy as follows: within 1 month prior to IMP initiation for etanercept and within 2 months prior to IMP initiation for other anti-TNF agents.
* Other experimental or commercially available biologic therapies for ankylosing spondylitis within 3 months prior to IMP initiation
* Anti-IL17 biologics (eg, brodalumab, secukinumab, ixekizumab) or anti-IL12/IL23 biologic therapy (eg, ustekinumab, briakinumab) at any time
* Rituximab at any time

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No